On November 5, 2026, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
|
Allogene Therapeutics is a clinical-stage biotechnology company developing genetically engineered allogeneic chimeric antigen receptor (CAR) T cell product candidates for the treatment of cancer and autoimmune diseases. The company focuses on creating "off-the-shelf" therapies derived from healthy donors, utilizing gene-editing technologies to minimize graft-versus-host disease and enhance cell persistence. Its core pipeline includes cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune conditions such as systemic lupus erythematosus. Allogene employs TALEN and CRISPR gene-editing technologies, the latter licensed from Arbor Biotechnologies, and operates its own cGMP manufacturing facility, Cell Forge 1, in Newark, California. The company was founded by Arie Belldegrun and David Chang, both former executives at Kite Pharma, to accelerate the development of allogeneic cell therapies. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage allogene.com |
| Sector Healthcare | IR page ir.allogene.com | |
|
Tags
allogeneic car t, cell therapy, gene editing, oncology, autoimmune disease, large b-cell lymphoma, renal cell carcinoma, systemic lupus erythematosus, immunotherapy, cema-cel, cemacabtagene ansegedleucel, ALLO-501A, ALLO-316, ALLO-329, Dagger, Cell Forge 1, ALPHA3, ALPHA2, TRAVERSE, Arbor Biotechnologies, Cellectis, Kite Pharma, Foresight Diagnostics, Natera
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 464.015M |
| Market cap (USD) | $ 464.015M |
| P/E | -2.13 |
| PEG | — |
| P/BV | 1.18 |
| P/S | — |
| P/OCF | -4.27 |
| P/FCF | -4.26 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -53.4% |
| ROI | -60.4% |
| ROIC | -49.7% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 16 |
| Quality score | -56.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||||
| Lease liabilities (USD) | — | 34.5M | 51.3M | 53.8M | 73.1M | 101M | 95.1M | 90.8M | 83.3M |
| Cash and deposits (USD) | 0.00 | 92.4M | 175M | 183M | 173M | 61.9M | 83.2M | 75.2M | 51.7M |
| Intangible assets (USD) | — | 754,000 | 151,000 | 0.00 | — | — | — | — | — |
| Right-of-use assets (USD) | — | 33M | 44.5M | 41.3M | 58M | 83.6M | 63.7M | 45.2M | 39.9M |
| Cash flow detail | |||||||||
| Operating cash flow (USD) | — | -44.7M | -137M | -115M | -185M | -221M | -238M | -200M | -149M |
| Purchases of property, plant and equipment (USD) | — | -3.23M | -50.8M | -66M | -21.4M | -5.19M | -1.52M | -694,000 | -386,000 |
| Change in payables (cash effect) (USD) | — | 8.8M | -985,000 | 615,000 | -767,000 | 4.87M | -7.5M | -503,000 | -1.23M |
| Share-based compensation (USD) | — | 18.6M | 46.1M | 65.3M | 80.8M | 83.6M | 66M | 51.7M | 37.6M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | -47.9M | -188M | -181M | -206M | -226M | -239M | -201M | -150M |
| Income detail | |||||||||
| Research and development expense (USD) | — | 152M | 145M | 193M | 220M | 256M | 243M | 192M | 150M |
| ↳ 5y CAGR | +9.9% | +5.9% | -4.9% | ||||||
| Total comprehensive income (USD) | — | -211M | -184M | -251M | -260M | -340M | -318M | -257M | -191M |
| Comprehensive income to owners (USD) | — | -211M | -184M | -251M | -260M | -340M | -318M | -257M | -191M |
| Reported | Mar 8, 2019 | Mar 8, 2019 | Feb 27, 2020 | Feb 25, 2021 | Feb 23, 2022 | Feb 28, 2023 | Mar 14, 2024 | Mar 13, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Oct 29, 2026 at 8:30 AM EDT
-
Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ET
-
ALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy Data from the Phase 1 RESOLUTION Study Scheduled for November 9, 2026 at 6:00 a.m. PT/9:00 a.m. ET
-
Preliminary Data from the Phase 1 RESOLUTION Trial will also be Presented at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its ALLO-329 autoimmune disease program.
Q3 2026 Financial Results and General Business Updates The Company will report third quarter 2026 financial results and provide a business update on November 5, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
-
Listen-Only Webcast of the Conference Call The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
-
Conference Call Registration for Questions If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
ALLO-329: Autoimmune Disease Program Update from ACR Convergence The Company will also host a webinar on Monday, November 9, 2026, at 6:00 a.m. PT/9:00 a.m. ET to review preliminary safety and efficacy data from the ongoing Phase 1 RESOLUTION study of ALLO-329 in adults with autoimmune diseases, including lupus, myositis and scleroderma. The webinar will precede the poster presentation of the first clinical results later that day at the American College of Rheumatology’s (ACR) annual meeting, ACR Convergence.
ALLO-329 is an investigational, next-generation off-the-shelf allogeneic CAR T designed to target both CD19 and CD70. It incorporates Allogene’s proprietary Dagger® technology, which is designed to enhance the expansion and persistence of allogeneic CAR T cells while potentially reducing or eliminating the need for conventional cytotoxic lymphodepletion.
-
Listen-Only Version of the Webinar The listen-only webinar will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
-
Webinar Registration for Questions If you would like the option to ask a question on the webinar, please use this link to register. Upon registering for the webinar, you will receive a personal PIN to access the call.
ACR Poster Presentations Details:
-
Session: Systemic Sclerosis & Related Disorders – Treatment Poster Session B
-
**Title:**Preliminary Safety and Efficacy Results from a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T-Cell Therapy for Autoimmune Disease
-
Presenting Author: Vivek Nagaraja, MD, FACR, Mayo Clinic Arizona
-
Date/Time: Monday, November 9, 2026, 10:30 a.m.-12:30 p.m. ET
About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Allogene may make from time to time with the SEC. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact: Christine Cassiano EVP, Chief Corporate Affairs & Brand Strategy Officer [email protected]

Print Page
Email Alerts
RSS Feeds
Investor Contacts
× Facebook Twitter LinkedIn E-Mail Tumblr Reddit WhatsApp Telegram
©2026 Allogene Therapeutics
Oct 26, 2026 at 8:30 AM EDT
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026.
-
UBS Global Biopharma ConferenceMonday, November 16 11:20 AM GMT / 6:20 AM ET London
-
Jefferies Global Healthcare ConferenceWednesday, November 18 9:30 AM GMT / 5:30 AM ET London
-
Piper Sandler 38th Annual Healthcare ConferenceWednesday, December 2 Time TBD New York
Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.
About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact: Christine Cassiano EVP, Chief Corporate Affairs & Brand Strategy Officer [email protected]

Print Page
Email Alerts
RSS Feeds
Investor Contacts
× Facebook Twitter LinkedIn E-Mail Tumblr Reddit WhatsApp Telegram
©2026 Allogene Therapeutics
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Allogene Therapeutics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| TMED | 0.21% | 23,151 | $ 48.154K | Jun 30, 2026 |
| RUSC | 0.20% | 76,529 | $ 159.18K | Jun 30, 2026 |
| MEDX | 0.18% | 16,776 | $ 34.894K | Jun 30, 2026 |
| VFMO | 0.09% | 882,910 | $ 1.766M | Aug 31, 2026 |
| FSEV | 0.06% | 1,970 | $ 4,097.60 | Jun 30, 2026 |
| FESM | 0.05% | 1,438,234 | $ 2.992M | Jun 30, 2026 |
| RESM | 0.02% | 304 | $ 632.32 | Jun 30, 2026 |
| DFAS | 0.00% | 1,648,632 | $ 1.363M | Nov 12, 2026 |
| DXUV | 0.00% | 58,034 | $ 47.994K | Nov 12, 2026 |
| DFAC | 0.00% | 241,276 | $ 199.535K | Nov 12, 2026 |


















Allogene Media/Investor Contact: Christine Cassiano EVP, Chief Corporate Affairs & Brand Strategy Officer